{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"75.7","upperLimit":"99.1","value":"93"},{"groupId":"OG001","lowerLimit":"77.2","upperLimit":"99.9","value":"95"},{"groupId":"OG002","lowerLimit":"62.1","upperLimit":"96.8","value":"85"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"20"}],"units":"Participants"}],"description":"Objective response rate (ORR) per investigator was defined as the percentage of subjects with complete response (CR) or partial response (PR) through the end of study or prior to the start of new anti-cancer treatment (including stem cell transplant, and excluding consolidative radiotherapy) other than the study treatment. For Parts A, B, and C the response was assessed using the Revised Response Criteria for Malignant Lymphoma (Cheson 2007).","dispersionType":"95% Confidence Interval","groups":[{"description":"Brentuximab vedotin (BV) monotherapy in adults age 60 and above with classical Hodgkin Lymphoma (cHL). BV (1.8 mg/kg) was administered as an intravenous (IV) infusion on Day 1 of each 21-day cycle.","id":"OG000","title":"Part A"},{"description":"BV in combination with dacarbazine as frontline therapy in adults aged 60 and above with cHL. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle. Dacarbazine (375 mg/m\\^2) was administered as an IV infusion on Day 1 of each 21-day cycle.","id":"OG001","title":"Part B"},{"description":"BV in combination with bendamustine as frontline therapy in adults aged 60 and above with cHL. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle. Bendamustine (70 mg/m\\^2) was administered as an IV infusion on Day 1 and Day 2 of each 21-day cycle.","id":"OG002","title":"Part C"}],"paramType":"NUMBER","populationDescription":"All subjects who received at least one dose of study drug","reportingStatus":"POSTED","timeFrame":"Up to 81 months","title":"Objective Response Rate (ORR) According to the Revised Response Criteria for Malignant Lymphoma (Parts A, B, and C)","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}